• Sung Reul Kim, Yong Soon Shin, Jeong Hoon Kim, Minseon Choi, and Sung-Hee Yoo.
• College of Nursing, Chonbuk National University, Jeollabuk-do, Korea.
• World Neurosurg. 2017 Feb 1; 98: 50-59.

ObjectiveObjectives of this study were to identify and compare symptom clusters in patients with meningioma and glioma and to assess and compare predictors of quality of life (QoL) in both patient groups.MethodsData were collected using the MD Anderson Symptom Inventory-Brain Tumor Module, Functional Assessment of Cancer Therapy-General, and Karnofsky Performance Sale. Of 158 participating patients, 77 had meningioma, and 81 had glioma.ResultsIn patients with meningioma, 4 symptom clusters were identified with 55.4% total variance: 1) physical, 2) cognitive, 3) elimination-appearance, and 4) motor-sensory symptoms. In patients with glioma, 4 clusters with 67.3% total variance were identified: 1) treatment-related, 2) cognitive, 3) appearance-elimination, and 4) gastrointestinal symptoms. Predictors of QoL in patients with meningioma were Karnofsky Performance Scale score (β = 0.41, P < 0.001), cognitive symptom cluster (β = -0.36, P < 0.001), and physical symptom cluster (β = -0.32, P = 0.001), whereas treatment-related symptom cluster (β = -0.55, P < 0.001) was identified as a predictor of QoL in patients with glioma.ConclusionsIn this study, the type and composition of symptom clusters differed between patients with meningioma and glioma. Our data also provide evidence that even when participants reported mild symptoms, these clusters could be used to predict QoL in patients with meningioma and glioma.Copyright © 2016 Elsevier Inc. All rights reserved.

31 keywords...

hide…